Heart failure & cardiomyopathies
Biomarker Profiles in Heart Failure with Preserved vs. Reduced Ejection Fraction: Results from the DIAST-CHF Study
Authors' conclusion
The identified proteins and signalling pathways offer new therapeutic and diagnostic approaches for patients with chronic HF.
Study context
- Population
- Patients with chronic heart failure (HF) (heart failure with preserved ejection fraction (HFpEF) or HFrEF) from the DIAST-CHF trial, representative subgroup aged 71 yearsHF n = 127
- Exposure
- HFpEF vs HFrEF vs healthy controls
- Healthy controln = 40reference
- Outcome
- Plasma levels of 180 biomarkers (proteomic approach)
Methodological detailsproteomic analysis, subgroup of the DIAST-CHF study
- Proteomic analysis
- Subgroup of the DIAST-CHF study
Main finding
As reported in the abstract
Differentially expressed plasma proteins
Proteins expressed significantly differently in both HF groups vs control
35
Unique proteins expressed in HFpEF
29
Unique proteins expressed in HFrEF
33
Observational data: associations, not effects.
Original publication
Biomarker Profiles in Heart Failure with Preserved vs. Reduced Ejection Fraction: Results from the DIAST-CHF Study. ESC Heart Fail. Published 2 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →